These ads allow local businesses to appear to their target audiences â € local community.
It is important that we continue to promote these ads as our local businesses need as much support as possible during these difficult times.
British scientists praised the « very exciting » news that a vaccine for the American Corona virus could prevent 94. 5% of people get Covid-19.
Temporary data from the US company Moderna indicates that its vaccine is very effective in preventing people from getting sick and it also works in all age groups, including the elderly..
The UK has not placed an order for the vaccine – which works similarly to the Pfizer vaccine – and it is not clear if the UK government can obtain any stock.
But scientists said the news is promising for other Covid-19 vaccines, and the vaccine for the University of Oxford and UK drug giant AstraZeneca is due to be announced in the coming days or weeks.
Moderna intends to apply for a permit for emergency use from the US Food and Drug Administration soon and will send more data on the vaccine’s effectiveness and safety.
The company’s final clinical trial is ongoing and has more than 30,000 people in the United States.
The interim analysis included 95 participants with confirmed cases of Covid-19, 90 of whom received a placebo and five of the active vaccine.
The 95 cases involved 15 elderly people – ages 65 and over. This included 20 people who were not white – including 12 of them from Hispanic or Latino / ethnic backgrounds, four African Americans, three Asian Americans and one who was multiracial..
Severe coronavirus cases, including 11 severe cases, were also examined in the first interim analysis.
All 11 cases occurred in the placebo group and no case occurred in the group that received the vaccine, currently known as mRNA-1273.
The vaccine was generally safe and well-tolerated, and the majority of adverse events were mild or moderate in severity, according to the report..
Severe events after the first dose included pain at the injection site and after the second dose included fatigue, muscle pain (muscle pain), joint pain (joint pain), headache, pain, and redness at the injection site.
Form 94. The effectiveness of this analysis could drop by 5% as more results are announced from the clinical trial.
Stephan Bansel, CEO of Moderna, said: “This is a pivotal moment in the development of our candidate vaccine Covid-19..
“Since early January, this virus has chased us with the intention of protecting the largest possible number of people around the world.
“This positive interim analysis from our Phase 3 study gave us the first clinical verification that our vaccine can prevent Covis-19 disease, including severe disease..
At the end of October, Moderna announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has started its vaccine continuous review process..
This means that the MHRA will review data as soon as it becomes available from ongoing studies, with the ability to determine if a vaccine should be licensed in the UK at some point..
This announcement comes one week after Pfizer / BioNTech released interim study data indicating their vaccine is more than 90% effective..
Peter Openshaw, professor of experimental medicine at Imperial College London, said: “This news from our country is very exciting and greatly reinforces optimism that we will have a good vaccine option in the next few months..
“First, we heard that Pfizer and BioNTech were 90% efficient, then the Russians said 92% and now our Moderna 94. 5%.
“This latest press release is based on a study of 30,000 adults in the United States, including many high-risk people or the elderly..
“This gives us confidence that the results are relevant to the people most at risk of contracting Covid-19 who are most in need of vaccines..
« Moderna also announced that the vaccine can be kept in the conventional refrigerator (-20 ° C) for up to six months, and that once the vaccine is thawed it can be kept for up to 30 days in the standard refrigerator (2 to 8 ° C). This makes getting vaccinated much easier.
Stephen Evans, professor of pharmacological epidemiology at the London School of Hygiene and Tropical Medicine, said: “This announcement from our Moderna is an additional encouragement that vaccines will not only be of acceptable efficacy but are much more effective. Than we expected.
This website and associated newspapers adhere to the Independent Journalism Standards Organization’s Code of Practice for Editors. If you have a complaint about editorial content of inaccuracy or intrusiveness, please contact the editor here. If you are not satisfied with the response provided, you may contact IPSO here.
© Copyright 2001-2020. This site is part of the Newsquest Verified Local Newspaper Network. Janet Corporation. Newsquest Media Group Ltd, Loudwater Mill, Station Road, High Wycombe, Buckinghamshire. HP10 9TY | 01676637 | Registered in England & Wales.
Vaccine, Moderna, Coronavirus, Student, Vaccine Trial, College
World News – United States – Covid-19 Vaccines: US-Led Moderna Vaccine – 94. 5 effective ????
. . Related Title :
– Vaccines for Covid-19: Moderna Gap, led by US & # 39; are 94. 5% efficacy & # 39;
– A college student from New England says it is part of the Moderna COVID-19 vaccine trial
– Taking Moderna Vaccine & # 39; CSEANDCHAR Medal of Honor # 39; For this junior college
– Corona Vaccine Update: Volunteer& # 39; Worsening health, fever and pain complaints during a recent vaccine trial
Donnez votre point de vue et aboonez-vous!
Votre point de vue compte, donnez votre avis
[maxbutton id= »1″]